S Drug Discovery Base and Pfizer&39.
ADDF, Pfizer’s CTI collaborate to advance development of new medications for Alzheimer’s disease The Alzheimer's Drug Discovery Base and Pfizer's Centers for Therapeutic Innovation announced today a collaboration designed to advance the development of new small-molecule medicines for Alzheimer's disease and related dementias. Within the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly spend money on translational research projects, with a focus on novel Alzheimer's medication targets. The cross-sector alliance is designed to enable project groups, comprised of Pfizer scientists and choose academic experts, to translate novel scientific research into effective therapeutics for Alzheimer's disease. (more…)